For its 90th anniversary, Farmak JSC launched new R&D laboratory and technology facility in Kyiv and plans to manufacture new science-intensive drugs, which will be compliant with the GMP requirements. The amount of investment is over UAH 100 million, for which Farmak plans to achieve payback over the next 2-3 years.
The new laboratory and technology facility will make it possible to conduct high quality development and promptly launch new medicinal products into market. The opportunity to manufacture similar products of the most recent generation will enable Farmak JSC to provide important import substitution to fill the niche of imported drugs in Ukraine with their domestic counterparts. The new facility makes it possible to set critical parameters, to build quality into the manufacturing process, and to achieve the target product profile as early as at the drug prototype stage.
The idea to create laboratory and technology facility with a pilot manufacturing site was a part of the plan to consolidate our R&D functions and close the gap which existed between development and manufacturing, says Andriy Goy, Head of R&D Department at Farmak JSC. Automated equipment, which provides downscaled reproduction of manufacturing procedures, and a whole multitude of state-of-the-art instruments to study physicochemical processes are now combined under the same roof. As a result, we obtained the scientific research and experiment area to test new and improve existing technologies for finished medicinal products.
The laboratories are provided with advanced technology equipment of such global manufacturers as Glatt, SBM, Urlinski, Belimed, De Ditrich, Gea, Sartorius, Malvern Instruments, and others. The design was produced by Unitechnology-UA, a Ukraine-based company, jointly with Farmak’s Design and Engineering Department.
The end-to-end principle of science and technology development implemented in the new R&D facility, from test tubes to pilot batches, makes it possible to conduct managed simulation, incremental scaling, technology transfer, and stand-alone preparation of test and clinical samples in GMP environment with the minimum intervention into the manufacturing operation plan.
Individual laboratory and manufacturing sites in the facility make it possible to develop and prepare hard dosage forms and aseptic liquid dosage forms in compliance with the GMP requirements.
As of today, the laboratory and technology facility is already producing clinical and registration batches; experimental batches are being prepared and their number is currently more than 150.
The 6th Conference of Farmak School of Young Scientists was held on 1 November 2018. 130 guests and employees of Farmak JSC attended the event; 26 reports were presented. This conference already enjoys popularity among students, young scientists, and post-graduate students. The School of Young Scientists is a platform for presenting scientific achievements a...
The strategic goal of Farmak JSC is to expand exports to the EU and to enter new markets Imposition of sanctions on Farmak JSC will not affect the company’s strategy and operations. Farmak JSC represents our state with dignity in the international arena: the company’s products are marketed in more than 20 countries of the […]
Farmak JSC received a Letter of gratitude from the Chairman of Committee on Public Health of the Verkhovna Rada of Ukraine for timely assistance during the elimination of the emergency situation in Chernihiv region caused by the explosion of ammunition warehouses near the town of Ichnia. Farmak often receives letters of gratitude as it always […]